Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KP746 advanced as abuse-resistant opioid analgesic
February 2016
SHARING OPTIONS:

CORALVILLE, Iowa—Specialty pharmaceutical company KemPharm Inc. has announced its plans to begin development of KP746, a recently identified oral prodrug of oxymorphone. The compound has the potential to be the first approved prodrug of oxymorphone, which is marketed under the brand name Opana for the management of pain. Preclinical study data suggest KP746 could offer enhanced bioavailability at typical therapeutic doses and abuse-deterrent features compared to standard oxymorphone, with the potential to be highly tamper-resistant.
 
“Oxymorphone is a commonly prescribed opioid analgesic, which, while effective at treating the symptoms of pain, has been found to have the potential for abuse and misuse similar to other opioids. Like our other opioid prodrug candidates, KP746 has features that may deter tampering and abuse on the molecular level, potentially limiting opioid exposure when misused either intranasally, intravenously, orally or when subjected to various physical and chemical manipulation techniques commonly used by opioid abusers,” said Dr. Travis C. Mickle, KemPharm president and CEO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.